Clinical-stage Pharmaceutical Company Announces Non-Small Cell Lung Cancer Discovery Breakthrough

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, has announced a breakthrough discovery in the fight against Non-Small Cell Lung Cancer (NSCLC). The Company's venture with Dr. Alon Silberman, MitoCareX Bio Ltd., confirmed a role of the SLC25 carrier protein in NSCLC cells with diverse genetic backgrounds. This article delves into the details of this discovery, its implications, and the broader context within which it sits. $SciSparc(SPRC.US)$